Iwai Y., Ishida M., Tanaka Y., Okazaki T., Honjo T., Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA. 2002;99(19):12293–12297. doi: 10.1073/pnas.192461099..
DOI: 10.1073/pnas.192461099
Sanmamed M.F., Chen L. A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization. Cell. 2018;175(2):313–326. doi: 10.1016/j.cell.2018.09.035..
DOI: 10.1016/j.cell.2018.09.035
Strome S.E., Dong H., Tamura H., Voss S.G., Flies D.B., Tamada K. et al. B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. Cancer Res. 2003;63(19):6501–6505. Available at: https://cancerres.aacrjournals.org/content/63/19/6501.https://cancerres.aacrjournals.org/content/63/19/6501
Wagner A.D., Grothe W., Haerting J., Kleber C., Grothey A., Fleig W.E. Chemotherapy in advanced gastric cancer: a systematic review and metaanalysis based on aggregate data. J Clin Oncol. 2006;24(18):2903–2909. doi: 10.1200/JCO.2005.05.0245..
DOI: 10.1200/JCO.2005.05.0245
Bang Y.J., Van Cutsem E., Feyereislova A., Chung H.C., Shen L., Sawaki A. et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687–697. doi: 10.1016/S0140-6736(10)61121-X..
DOI: 10.1016/S0140-6736(10)61121-X
Essadil I., Sair K., Lalya I., Abderrahim E., Khouchani M., Belbaraka R. Targeted Therapies in Metastatic Gastric Cancer: Challenges and Perspectives. Chemotherapy: Open Access. 2018;7(2). Available at: https://www.longdom.org/open-access/targeted-therapies-in-metastatic-gastric-cancer-challenges-and-perspectives-2167-7700-1000260.pdf.https://www.longdom.org/open-access/targeted-therapies-in-metastatic-gastric-cancer-challenges-and-perspectives-2167-7700-1000260.pdf
Buchbinder E.I., Desai A. CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition. Am J Clin Oncol. 2016;39(1):98–106. doi: 10.1097/COC.0000000000000239..
DOI: 10.1097/COC.0000000000000239
Nagatsuma A.K., Aizawa M., Kuwata T., Doi T., Ohtsu A., Fujii H., Ochiai A. Expression profiles of HER2, EGFR, MET and FGFR2 in a large cohort of patients with gastric adenocarcinoma. Gastric Cancer. 2015;18(2):227–238. doi: 10.1007/s10120-014-0360-4..
DOI: 10.1007/s10120-014-0360-4
Fuchs C., Tomasek J., Yong C.J., Dumitru F., Passalacqua R., Goswami C. et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2014;383(9911):31–39. doi: 10.1016/S0140-6736(13)61719-5..
DOI: 10.1016/S0140-6736(13)61719-5
Bilgin B., Sendur M.A., Bülent Akinci M.B., Şener Dede D., Yalçin B. Targeting the PD-1 pathway: a new hope for gastrointestinal cancers. Curr Med Res Opin. 2017;33(4):749–759. doi: 10.1080/03007995.2017.1279132..
DOI: 10.1080/03007995.2017.1279132
Wang D., Lin J., Yang X., Long J., Ba Y., Yang X. et al. Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies. J Hematol Oncol. 2019;12(1):42. doi: 10.1186/s13045-019- 0730-9..
DOI: 10.1186/s13045-019- 0730-9
Ray K. Therapy: The ATTRACTION of nivolumab for gastric and gastrooesophageal junction cancer. Nat Rev Gastroenterol Hepatol. 2017;14(12):690. doi: 10.1038/nrgastro.2017.157..
DOI: 10.1038/nrgastro.2017.157
Boku N., Ryu M.H., Kato K., Chung H.C., Minashi K., Lee K.-W. et al. Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4). Ann Oncol.2019;30(2):250–258. doi: 10.1093/annonc/mdy540..
DOI: 10.1093/annonc/mdy540
Imazeki H., Kato K., Boku N. Nivolumab Treatment for the Patients with Gastric Cancer-Present and Future. Gan To Kagaku Ryoho. 2019;46(10):1513– 1523. (In Japan.) Available at: https://pubmed.ncbi.nlm.nih.gov/31631132.https://pubmed.ncbi.nlm.nih.gov/31631132
Kato K., Satoh T., Muro K., Yoshikawa T., Tamura T., Hamamoto Y. et al. A subanalysis of Japanese patients in a randomized, double-blind, placebo-controlled, phase 3 trial of nivolumab for patients with advanced gastric or gastro-esophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2). Gastric Cancer. 2019;22(2):344–354. doi: 10.1007/s10120-018-0899-6..
DOI: 10.1007/s10120-018-0899-6
Chen L.T., Satoh T., Ryu M.H., Chao Y., Kato K., Chung H.C. et al. A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data. Gastric Cancer. 2020;23(3):510–519. doi: 10.1007/s10120-019-01034-7..
DOI: 10.1007/s10120-019-01034-7
Smyth E.C., Moehler M. Late-line treatment in metastatic gastric cancer: today and tomorrow. Ther Adv Med Oncol. 2019;11:1758835919867522. doi: 10.1177/1758835919867522..
DOI: 10.1177/1758835919867522
Zhao P., Li L., Jiang X., Li Q. Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy. J Hematol Oncol. 2019;12(1):54. doi: 10.1186/s13045-019-0738-1..
DOI: 10.1186/s13045-019-0738-1
Figueroa-Protti L., Soto-Molinari R., Calderón-Osorno M., Mora J., AlpízarAlpízar W. Gastric Cancer in the Era of Immune Checkpoint Blockade. J Oncol. 2019;2019:1079710. doi: 10.1155/2019/1079710..
DOI: 10.1155/2019/1079710
Ilson D.H. Advances in the treatment of gastric cancer. Curr Opin Gastroenterol. 2017;33(6):473–476. doi: 10.1097/MOG.0000000000000395..
DOI: 10.1097/MOG.0000000000000395
Muro K., Chung H.C., Shankaran V., Geva R., Catenacci D., Gupta S. et al. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. Lancet Oncology. 2016;17(6):717–726. doi: 10.1016/S1470-2045(16)00175-3..
DOI: 10.1016/S1470-2045(16)00175-3
Eso Y., Shimizu T., Takeda H., Takai A., Marusawa H. Microsatellite instability and immune checkpoint inhibitors: toward precision medicine against gastrointestinal and hepatobiliary cancers. J Gastroenterol. 2020;55(1):15– 26. doi: 10.1007/s00535-019-01620-7..
DOI: 10.1007/s00535-019-01620-7
Pardoll D.M. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–264. doi: 10.1038/nrc3239..
DOI: 10.1038/nrc3239
Fuchs С.S., Dоi T., Jang R.W., Muro K., Satoh T., Machado M. et al. Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial. JAMA Oncol. 2018;4(5):e180013. doi: 10.1001/jamaon-col.2018.0013..
DOI: 10.1001/jamaon-col.2018.0013
Kato K., Shah M.A., Enzinger P., Bennouna J., Shen L., Adenis A. et al. KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer. Future Oncol. 2019;15(10):1057–1066. doi: 10.2217/fon-2018-0609..
DOI: 10.2217/fon-2018-0609
Herbst R.S., Arkenau H.T., Santana-Davila R., Calvo E., Paz-Ares L., Cassier P.A. et al. Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial. Lancet Oncol. 2019;20(8):1109–1123. doi: 10.1016/S1470-2045(19)30458-9..
DOI: 10.1016/S1470-2045(19)30458-9
Bang Y.J., Kang Y.K., Catenacci D.V., Muro K., Fuchs C.S., Geva R. et al. Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study. Gastric Cancer. 2019;22(4):828–837. doi: 10.1007/s10120-018-00909-5..
DOI: 10.1007/s10120-018-00909-5
Eso Y., Shimizu T., Takeda H., Takai A., Marusawa H. Microsatellite instability and immune checkpoint inhibitors: toward precision medicine against gastrointestinal and hepatobiliary cancers. J Gastroenterol. 2020;55(1):15–26. doi: 10.1007/s00535-019-01620-7..
DOI: 10.1007/s00535-019-01620-7
Bang Y.J., Cho J.Y., Kim Y.H., Kim J.W., Di Bartolomeo M., Ajani J.A. et al. Efficacy of Sequential Ipilimumab Monotherapy versus Best Supportive Care for Unresectable Locally Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer. Clin Cancer Res. 2017;23(19):5671–5678. doi: 10.1158/1078-0432.CCR-17-0025..
DOI: 10.1158/1078-0432.CCR-17-0025
Oh D.Y., Al-Batran S.E., Chung H.C., Hollebecque A., Iqbal S., Kim K.-P. et al. MORPHEUS: A phase Ib/II trial platform evaluating the safety and efficacy of multiple cancer immunotherapy (CIT) combinations in patients (pts) with gastric or pancreatic cancer. J Clin Oncol. 2018;36(15S):4134. doi: 10.1200/JCO.2018.36.15_suppl.TPS4134..
DOI: 10.1200/JCO.2018.36.15_suppl.TPS4134
De Rosa S., Sahnane N., Tibiletti M.G., Magnoli F., Sessa F., Chiaravalli A.M. et al. EBV⁺ and MSI Gastric Cancers Harbor High PD-L1/PD-1 Expression and High CD8⁺ Intratumoral Lymphocytes. Cancers (Basel). 2018;10(4):102. doi: 10.3390/cancers10040102..
DOI: 10.3390/cancers10040102
Fukuoka S., Hara H., Takahashi N., Kojima T., Kawazoe A., Asayama M. et al. Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603). J Clin Oncol. 2020;38(18):2053– 2061. doi: 10.1200/JCO.19.03296..
DOI: 10.1200/JCO.19.03296
Bouchez C., Kempf E., Tournigand C. MSI Metastatic solid tumors treatment and immunotherapies. Bull Cancer. 2019;106(2):143–150. (In French) doi: 10.1016/j.bulcan.2019.01.008..
DOI: 10.1016/j.bulcan.2019.01.008
Janjigian Y.Y., Bendell J., Calvo E., Kim J.W., Ascierto P.A., Sharma P. et al. CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer. J Clin Oncol. 2018;36(28):2836–2844. doi: 10.1200/JCO.2017.76.6212..
DOI: 10.1200/JCO.2017.76.6212
Zayac A., Almhanna K. Esophageal, gastric cancer and immunotherapy: small steps in the right direction? Transl Gastroenterol Hepatol. 2020;5:9. doi: 10.21037/tgh.2019.09.05..
DOI: 10.21037/tgh.2019.09.05
Shitara K., Özgüroğlu M., Bang Y.J., Di Bartolomeo M., Mandalà M., Ryu M.H. et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet. 2018;392(10142):123–133. doi: 10.1016/S0140-6736(18)31257-1..
DOI: 10.1016/S0140-6736(18)31257-1